Hims & Hers (HIMS): Betting $47M against the FTC [Q2 2026]

Hims & Hers printed massive subscriber growth in Q2 2026, but the upfront costs of an aggressive global weight-loss expansion and a high-stakes regulatory court battle have gutted their cash flow.In ~10 minutes:• Why management chose a $47.5M legal contingency over settling with the FTC.• How branded GLP-1 inventory flipped free cash flow violently negative.• The new $400M receivables facility designed to front weight-loss capital.• Pivoting from software to physical drug compounding at a new Menlo Park lab.Top-line momentum remains red-hot, but Hims is actively sacrificing near-term margins and liquidity to establish a sprawling global footprint. We unpack whether this radical evolution into a vertically integrated pharmaceutical operator justifies the heavy operational burn. 📉Hims & Hers Health, Inc. (HIMS) | Q2 FY2026AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.